Recently, NMPA passed the priority review procedure and conditionally approved the marketing of the Class 1 innovative drug pratinib capsules declared by Blueprint Medicines Corporation. Pratinib is a receptor tyrosine kinase RET (Rearranged during Transfection) inhibitor. It can selectively inhibit RET kinase activity, inhibit the phosphorylation of RET and its downstream molecules in a dose-dependent manner, and effectively inhibit the expression of RET (wild-type and multiple Kind of mutant) cell proliferation.

This drug is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patients who have previously received platinum-containing chemotherapy for RET gene fusion positive. The marketing of this variety provides a new treatment option for adult patients with locally advanced or NSCLC.